| 產(chǎn)品名稱 |
131-94H4 |
| 商品貨號 |
B163561 |
| Organism |
Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma) |
| Tissue |
spleen |
| Cell Type |
hybridoma: B lymphocyte |
| Product Format |
frozen |
| Morphology |
lymphoblast |
| Culture Properties |
suspension |
| Biosafety Level |
1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Age |
adult |
| Gender |
female |
| Strain |
129GIX+ |
| Applications |
Protein is also detected in selected embryo tissues. Animals were immunized with a synthetic polypeptide with the sequence RRKVEQEGYPQESSKAG(C) corresponding to peptides 119 to 135 of the MYB oncogene formerly v-myb (residues 2 to 18). |
| Storage Conditions |
liquid nitrogen vapor phase |
| Derivation |
Animals were immunized with a synthetic polypeptide with the sequence RRKVEQEGYPQESSKAG(C) corresponding to peptides 119 to 135 of the MYB oncogene formerly v-myb (residues 2 to 18). Spleen cells were fused with Sp2/0 myeloma cells. Using immunoblot techniques, the antibody recognizes a 25 kd protein in BM2 cells and a protein of approximately 100 kd in Molt 4 cells. Protein is also detected in selected embryo tissues.
The IgG1 and IgG2b reactivities of the antibody with the v-myb peptide (119 to 135) were confirmed by ELISA. IgG1 was strongly positive while IgG2b was only slightly reactive. |
| Clinical Data |
female |
| Genes Expressed |
immunoglobulin; monoclonal antibody; against a synthetic v-myb oncogene peptide |
| Cellular Products |
immunoglobulin; monoclonal antibody; against a synthetic v-myb oncogene peptide |
| Comments |
Animals were immunized with a synthetic polypeptide with the sequence RRKVEQEGYPQESSKAG(C) corresponding to peptides 119 to 135 of the MYB oncogene formerly v-myb (residues 2 to 18). Spleen cells were fused with Sp2/0 myeloma cells. Using immunoblot techniques, the antibody recognizes a 25 kd protein in BM2 cells and a protein of approximately 100 kd in Molt 4 cells. Protein is also detected in selected embryo tissues.
The IgG1 and IgG2b reactivities of the antibody with the v-myb peptide (119 to 135) were confirmed by ELISA. IgG1 was strongly positive while IgG2b was only slightly reactive. |
| Complete Growth Medium |
The base medium for this cell line is ATCC-formulated Dulbecco's Modified Eagle's Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
|
| Subculturing |
Protocol: Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 1 to 2 X 10(5) viable cells/ml. Interval: Maintain cell density between 1 X 10(5) and 1 X 10(6) viable cells/ml. Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density) |
| Cryopreservation |
Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO Storage temperature: liquid nitrogen vapor phase |
| Culture Conditions |
Atmosphere: air, 95%; carbon dioxide (CO2), 5% Temperature: 37.0°C |
| Isotype |
IgG1 kappa |
| Name of Depositor |
National Cancer Institute |
| Deposited As |
mouse (B cell); mouse (myeloma) |
| References |
Animals were immunized with the synthetic peptide RRKVEQEGYPQESSKAG(C) corresponding to residues 119 through 135 of the MYB sequence (formerly residues 2 through 18 of the v-myb sequence).
Using immunoblot techniques, the antibody recognizes a 25 kd protein in BM2 cells and a protein of approximately 100 kd in Molt 4 cells. Protein is also detected in selected embryo tissues. The IgG1 and IgG2b reactivities of the antibody with the v-myb peptide (119 to 135) were confirmed by ELISA. IgG1 was strongly positive while IgG2b was only slightly reactive.
|
